PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma

Francesco Sabbatino¹*, Vincenzo Villani¹*, Jennifer H. Yearley², Vikram Deshpande³, Lei Cai¹, Ioannis T. Konstantinidis¹, Christina Moon², Sjoerd Nota⁴, Yangyang Wang¹, Ahmad Al-Sukaini¹, Andrew X. Zhu⁵, Lipika Goyal⁵, David T. Ting⁵, Nabeel Bardeesy⁵, Theodore S. Hong⁶, Carlos Fernandez-del Castillo¹, Kenneth K. Tanabe¹, Keith D. Lillemoe¹, Soldano Ferrone¹,⁴, Cristina R. Ferrone¹

Departments of ¹Surgery, of ³Pathology, of ⁴Orthopaedic Surgery, of ⁶Radiation Oncology, and ⁵Cancer Center, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114. ²Merck Research Laboratories, 901 S. California Ave, Palo Alto, CA 94304. * These authors contributed equally to this work.

Corresponding Author:

Cristina R. Ferrone, M.D.
Department of Surgery
Massachusetts General Hospital
15 Parkman St, WACC 460
Boston, MA 02114
Phone: 617-643-6189
FAX: 617-643-6116
cferrone@mgh.harvard.edu

Keywords: PD-L1, HLA class I, immune escape mechanisms, T cell infiltrate, intrahepatic cholangiocarcinoma

Running title: PD-L1 and HLA class I in intrahepatic cholangiocarcinoma

Financial support: This work was supported by a grant from the Cholangiocarcinoma Foundation, a grant from the Andrew L. Warshaw, M.D., Institute for Pancreatic Cancer
Research, the Public Health Service (PHS) Grant R21 CA 164756, awarded by the National Cancer Institute and generous donations from patients and their families affected by cholangiocarcinoma. FS is the recipient of a Post-Doctoral Fellowship awarded by the Fondazione Umberto Veronesi. VV is the recipient of a Research Fellowship from the Centro per la Comunicazione e la Ricerca of the Collegio Ghislieri of Pavia.

Disclaimer: Jennifer H. Yearley and Christina Moon are full time employees of Merck Research Laboratories. The other authors have no conflicts of interest to declare.

Word count: 3447

Number of figures: 5 (+ 3 supplementary figures)

Number of tables: 1 (+ 1 supplementary table)
STATEMENT OF TRANSLATIONAL RELEVANCE: The lack of effective therapy for intrahepatic cholangiocarcinoma (ICC) has prompted us to investigate the expression of the checkpoint inhibitors PD-1 and PD-L1 and of HLA class I antigens in this malignancy, since these molecules play a role in the clinical response to immunotherapy with checkpoint inhibitor-specific monoclonal antibodies (mAbs). The latter type of immunotherapy is effective in various types of malignancies. Immunostaining with mAbs detected HLA class I defects in 60% of ICC tumors and PD-L1 expression in 30%. Patients bearing tumors with HLA class I defects and PD-L1 expression had a significantly reduced survival. This association is likely to reflect the role of patients’ immune response to their tumors. Our findings provide a rationale to implement anti–PD-1/PD-L1 based immunotherapy for the treatment of ICC and to use HLA class I antigen expression to select patients who may benefit from this type of immunotherapy.
ABSTRACT

PURPOSE: More effective therapy is needed for intrahepatic cholangiocarcinoma (ICC). The encouraging clinical results obtained with checkpoint molecule-specific monoclonal antibodies (mAbs) have prompted us to investigate whether this type of immunotherapy may be applicable to ICC. The aims of this study were to determine whether 1) patients mount a T-cell immune response to their ICC, 2) checkpoint molecules are expressed on both T-cells and tumor cells, and 3) tumor cells are susceptible to recognition by cognate T-cells.

EXPERIMENTAL DESIGN: Twenty-seven ICC tumors were analyzed for i) lymphocyte infiltrate ii) HLA class I and HLA class II expression, and iii) PD-1 and PD-L1 expression by T-cells and ICC cells, respectively. The results of this analysis were correlated with the clinicopathological characteristics of the patients investigated.

RESULTS: Lymphocyte infiltrates were identified in all tumors. PD-L1 expression and HLA class I antigen expression by ICC cells was observed in 8 and 11, respectively, of the 27 tumors analyzed. HLA class I antigen expression correlated with CD8+ T cell infiltrate. Furthermore, positive HLA class I antigen expression in combination with negative/rare PD-L1 expression was associated with favorable clinical course of the disease.

CONCLUSIONS: ICC patients are likely to mount a T cell immune response against their own tumors. Defects in HLA class I antigen expression in combination with PD-L1 expression by ICC cells provide them with an immune escape mechanism. This mechanism justifies the implementation of immunotherapy with checkpoint molecule-
specific mAbs in patients bearing ICC tumors without defects in HLA class I antigen expression.
INTRODUCTION

Intrahepatic cholangiocarcinoma (ICC) accounts for 2-3% of all gastrointestinal cancers, however, the incidence is rising globally(1). The prognosis of ICC remains very poor, with surgical resection offering the only hope for cure(2). However, even with a complete resection, the majority of patients develop recurrent and metastatic disease, resulting in a 5-year overall survival (OS) rate of 10-40%(3). Therefore, novel effective therapies are urgently needed for ICC patients. In recent clinical trials the administration of monoclonal antibodies (mAbs) which inhibit the interaction of immune regulatory checkpoint molecules such as Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) with their ligands CD80, CD86 and programmed cell death ligand 1 (PD-L1), has had a major impact on the clinical course of various types of malignancies(4-14). However the efficacy of this novel immunotherapeutic strategy is limited to less than 30% of patients. These findings have stimulated interest in characterizing the host’s immune response, as well as the potential mechanism(s) underlying a tumor’s ability to escape the immune attack.

For many malignancies, tumor-infiltrating lymphocytes are evidence that patients are mounting an immune response to their own cancer (15, 16). However the therapeutic efficacy of this immune response is limited by the multiple escape mechanisms that tumor cells develop to avoid immune recognition and destruction. These mechanisms include i) inhibition of the activation of cognate cytotoxic T lymphocytes (CTLs) due to the interaction of co-inhibitory molecules such as CTLA-4 and PD-1 with their own ligands(17) and ii) defects in HLA class I antigen processing machinery (APM) components, which result in a defective synthesis and/or expression of HLA class I
antigen-tumor antigen-derived peptide complexes. The latter mediate the interaction between tumor cells and cognate CTLs (18, 19). Defects in HLA class I APM components, frequently identified in malignant neoplasms, are associated with a reduced OS in various types of cancer (20, 21). The tumor antigen-specific immune response can also be modulated by the de novo expression of HLA class II antigens by tumor cells, which has been reported in a number of malignancies (20). Tumor cells that express the HLA class II-peptide complex can act as antigen presenting cells (APCs) and interact with CD4+ helper cells, which can in turn induce growth and differentiation of CD8+ CTLs. The HLA class II-peptide complex can however activate subpopulations of CD4+ cells with immunosuppressive properties (Tregs), which can inhibit the tumor antigen-specific T cell immune response. This double-edged effect of HLA class II-peptide-CD4+ cell interactions could explain why HLA class II expression is correlated with favorable prognosis in some types of tumors, but with a poor prognosis in others (22-25).

To the best of our knowledge, only limited information is available regarding a patient's immune response against ICC and its role in the clinical course of the disease. Therefore, the first aim of this study was to test whether ICC patients can mount an immune response against their own tumors, as indicated by the presence of lymphocyte infiltrates. The second aim was to understand possible immune escape mechanisms, such as defects in HLA class I antigen expression and HLA class II de novo expression by tumor cells. The third aim was to evaluate a possible second immune escape mechanism by analyzing the expression of the inhibitory molecule PD-1 and its ligand PD-L1. The interaction between PD-1 and PD-L1 will affect a patient's ability to mount...
an immune response to his own tumor. The clinical significance of this immununologic analysis has been assessed by correlating these results with the patients’ clinical course of the disease.
MATERIAL AND METHODS

Tissues

Tumor specimens from primary ICC lesions were obtained from patients who underwent hepatectomies at the Massachusetts General Hospital, between 2004 and 2013. ICC tumors were confirmed histopathologically by a GI pathologist (VD) according to the AJCC (7th Edition) and the WHO classification systems. Clinicopathological information available included patient age, gender, margin resection status, histological grading, tumor stage, tumor size, lymph node involvement, presence of single or multiple lesions, presence of vascular invasion and overall survival. This study was approved by the institutional review board.

Monoclonal antibodies

The mAb HCA2, which recognizes $\beta_2$m-free HLA-A (excluding -A24), -B7301, and -G heavy chains (26, 27); mAb HC10, which recognizes $\beta_2$m-free HLA-A3, -A10, -A28, -A29, -A30, -A31, -A32, -A33, and all $\beta_2$m-free -HLA-B (excluding -B5702, -B5804, and -B73) and -HLA-C heavy chains (26-28); and mAb LGII-612.14 which recognizes HLA-DR, DQ and DP $\beta$ chains were developed and characterized as described(29). PD-L1 antibody clone 22C3 was generated in the Merck Research Laboratories. A list of the other commercially available mAbs is provided in the supplemental material.

Immunohistochemical staining
Four-µm formalin-fixed, paraffin-embedded tissue sections from ICC tumor samples were used as substrates in immunohistochemical (IHC) reactions. IHC staining with HC10, HCA2, LGII-612.14 and anti-nitrotyrosine mAbs was performed as described previously (30). The staining with anti-PD-1 and anti-PD-L1 mAb as well as the slide scoring are described in the supplemental material.

**Statistical analysis**

Statistical analysis was performed with the Stata Statistical Software, Release 13. (StataCorp LP, College Station, TX). Correlation of HLA class I antigen, nitrotyrosine, PD-1 and PD-L1 expression with the number of CD8+ and CD4+ cells infiltrating the FS and TLs of tumor lesions were analyzed by Spearman’s rank correlation coefficient. Correlation of PD-1 and PD-L1 expression with HLA class I antigen expression was analyzed by Fisher exact test. Differences in the expression levels of variables according to histopathologic and clinical characteristics were analyzed using the Mann-Whitney U-test or the Kruskal-Wallis rank test. Overall survival measured as cause-specific survival (CSS) was calculated using the Kaplan-Meier method. Time was defined as the interval between the date of diagnosis to the date of disease-specific death (event) or that of last follow-up visit (censored). A log-rank test was used for screening the possible prognostic factors in relation to the patients’ survival. $P < 0.05$ was considered to be statistically significant. All tests used were two-tailed.
RESULTS

Patients characteristic and tumor specimens

Twenty-seven patients with a median age of 64 years (range, 38-81 years) underwent surgical resection of their ICCs. Table 1 summarizes the patients’ clinicopathologic characteristics.

Lymphocyte infiltrate in primary ICC lesions

To investigate whether ICC patients developed an immune response against their own tumors we analyzed the presence of CD8+ T cells and CD4+ cells in ICC lesions. Staining with CD8- and CD4-specific mAbs was scored by counting the number of stained infiltrating cells in four high-powered fields of the fibrous septa (FS) and tumor lobules (TLs) of ICC lesions. An immune infiltrate was present in all the tumors analyzed (100.0%). Interestingly there was a significant difference in the number of CD8+ T lymphocytes in the FS when compared to that within TLs (Figure 1A-1B). The number of CD8+ T cells ranged between 9.2 and 250.0 (mean n = 103.0 ± 68.1) in FS, as compared to 0.2 and 33.7 (mean n = 12.0 ± 10.2) in TLs. In every tumor the number of CD8+ T cells was higher in FS than in the corresponding TLs (Mann-Whitney U-test P<0.00001) (Figure 1A-1B).

There was a positive association between the two populations (Spearman’s rho = 0.7570, P < 0.0001): ICC tumors displaying a higher number of CD8+ T cells in the FS also had a higher number of CD8+ T cells infiltrating the TLs. This association was not found when evaluating CD4+ cells (Figure 1C-1D). Although it did not reach statistical
significance, the number of CD4+ cells demonstrated a negative trend of association with the number of CD8+ T cells in the FS (Spearman's rho = -0.3524, P = 0.0774). This inverse association between CD4+ and CD8+ infiltrate could be a consequence of the CD4 antigen being expressed by populations of immunosuppressive leukocytes, including regulatory T cells, dendritic cells, monocytes and macrophages.

Nitrotyrosine expression in primary ICC lesions

We then investigated whether the presence of reactive nitrogen plays a role in the differential distribution of CD8+ T cells within FS and TLs(31). Staining with the nitrotyrosine-specific mAb showed that the T lymphocyte distribution mirrored the nitrotyrosine staining (Figure S1). Cancer cell staining intensity for nitrotyrosine negatively correlated with the number of CD8+ T cells both in FS and in TLs (CD8+ T cells in FS Spearman's rho = -0.6149, P = 0.0006; CD8+ T cells in TLs Spearman's rho = -0.7410, P = 0.0000). In addition nitrotyrosine expression was higher in TLs than in FS; in the latter more CD8+ T cells were concentrated at the border of the tumor lesion. Therefore these results suggest that the production of nitrogen reactive species limits the infiltration of CTLs in TLs.

Association of HLA class I and HLA class II antigen expression in primary ICC lesions with tumor lymphocyte infiltration.

HLA class I antigen expression was down-regulated in a total of 16 (59.2%) out of the 27 ICC lesions analyzed. Specifically, HLA class I antigen expression was heterogeneous in 10 (37.0%) lesions, and was not detectable in 6 (22.2%).
Representative staining patterns of ICC lesions with HLA class I antigen-specific mAbs are shown in Figure 1E-1H. The number of CD8+ T cells within TLs and FS correlated with HLA class I antigen expression (FS Spearman’s rho = 0.8101, P = 0.0000; TLs Spearman’s rho = 0.5679, P = 0.0020) (Figure 2). In contrast, the number of CD4+ cells in FS and TLs was inversely correlated with HLA class I antigen expression (Spearman’s rho = -0.6045, P = 0.0102).

HLA class II antigens were expressed on ICC cells in 15 (55.5%) of the 27 tumors analyzed; the expression was scored as positive in 4 (14.8%) lesions and heterogeneous in 11 (40.7%). HLA class II antigen expression was associated neither with HLA class I antigen expression nor with CD4+ and CD8+ T cell infiltration.

HLA class II antigens were expressed on tumor-infiltrating leukocytes both in FS and within TLs of all the tumors. This expression pattern is compatible with the possibility that tumor-infiltrating lymphocytes are activated and/or that dendritic cells/macrophages are present in the tumor (Figure S2).

PD-1 and PD-L1 expression in primary ICC lesions and their interaction with tumor-infiltrating lymphocytes

Our third aim was to determine whether a patient’s immune response is affected by the expression of PD-1 and/or PD-L1 in ICC tumors. All tumors (100.0%) expressed PD-1, except for one which could not be analyzed because of the lack of sufficient tumor tissue in the sample (Figure 3A-3C). PD-1 was expressed on tumor-infiltrating lymphocytes, but was not detected on ICC cells. Prevalence of PD-1 positive cells varied from rare (1) to very high (5). PD-1+ cells had a low-to-moderate prevalence in
the majority of the lesions; specifically the score was low in 11 (42.3%) and moderate in 6 (23.1%) lesions. The prevalence of PD-1+ cells correlated with the degree of lymphocyte infiltration and was higher in FS than in TLs. A trend was also found between PD-1 expression and the number of CD8+ T cells in FS (Kruskal-Wallis $P = 0.0832$). Interestingly, PD-1 expression was strongly correlated with HLA class II antigen expression (Spearman's rho = 0.6830, $P = 0.0001$).

PD-L1 was expressed in all the tumors analyzed (100%), however in only 8 tumors (29.6%) was PD-L1 expressed on cancer cells (Figure 3E-3H). The staining was scored as rare, low, moderate, high and very high in 1 (12.5%), 2 (25.0%), 2 (25.0%), 2 (25.0%) and 1 (12.5%) lesions, respectively. In these lesions, PD-L1 expression was found on tumor cells as well as on tumor-infiltrating leukocytes and macrophages.

In the remaining 19 ICC lesions PD-L1 expression was restricted to non-cancer cells including tumor-infiltrating leukocytes. In the latter case PD-L1 was mainly expressed in the FS. No correlation was identified between PD-L1 expression on ICC cells and the number of infiltrating CD8+ or CD4+ leukocytes. However, PD-L1 expression was correlated with the number of CD8+ T cells in FS (Spearman's rho = 0.5951, $P = 0.0011$). This correlation was also influenced by HLA class I antigen expression: in tumors with negative/rare PD-L1 expression and positive HLA class I antigen expression ($n= 9$) the mean number of infiltrating CD8+ T cells was significantly higher than in lesions with high PD-L1 expression (PD-L1 score $\geq 2$), negative/heterogeneous HLA class I antigen expression or a combination of both ($n= 18$) (mean $n = 163.7 \pm 66.6$ vs mean $n = 73.0 \pm 45.7$, Wilcoxon rank-sum $P = 0.0024$) (Figure 4).
Correlation of HLA class I antigen, HLA class II antigen, PD-1 and PD-L1 expression and tumor-infiltrating lymphocytes with the staging of ICC lesions and ICC patients’ OS.

To determine whether the patient population analyzed in this study was representative of the ICC population, standard clinicopathological characteristics were correlated with patients’ OS. In agreement with what has been observed in larger patient populations, T staging (log-rank $P = 0.059$), single lesions (log-rank $P = 0.024$) and stage (log-rank $P = 0.006$) significantly correlated with OS. Therefore, we feel that this cohort of patients is representative of the ICC population.

Next we assessed the clinical relevance of the immunophenotypic staining of the ICC tumors by correlating these data with the clinicopathological characteristics of the patient population (Table S1). A negative correlation was identified between HLA class I antigen expression and tumor stage (Fisher’s exact = 0.029). ICC tumors with down-regulation of their HLA class I antigen expression presented with a more advanced stage than tumors with high HLA class I antigen expression levels. T staging was positively correlated with both margins of resection (Spearman’s rho = 0.5239, $P = 0.0050$) and PD-L1 expression by tumor cells (Fisher’s exact = 0.016). Tumors with higher T stages expressed more PD-L1 than early T stage ICCs. The number of CD8+ T cells and CD4+ leukocytes, HLA class I antigen expression by ICC cells, and PD-1 and PD-L1 expression in the tumor microenvironment were not associated with patients’ survival. In contrast, positive HLA class I antigen expression in combination with negative/rare PD-L1 expression (n=9) in ICC tumors was associated with a significantly longer patient survival (log-rank $P = 0.0472$) (Figure 5) as compared to high PD-L1.
expression (PD-L1 score ≥ 2), negative/heterogeneous HLA class I antigen expression or a combination of both (n = 18). When HLA class I antigen expression was stratified in negative/heterogeneous or positive tumors, patients with HLA class I antigen positive and PD-L1 negative tumors (n=9) had a significantly longer survival than patients who expressed both HLA class I antigens and PD-L1 (n=2) (log-rank P = 0.0306) (Figure 5).
DISCUSSION

The present study has provided for the first time evidence that ICC patients mount a T cell immune response against their own tumors, since lymphocyte infiltrates are present in all the tumors analyzed. Furthermore lymphocytes bear an activated phenotype as they express HLA class II antigens. Lymphocytes appear to impose a selective pressure on tumor cell populations, since HLA class I antigen defects have been found in more than 50% of the tumors analyzed. These defects reflect the outgrowth of tumor cells which escape from recognition and destruction by the host immune system because of abnormalities in HLA class I antigens. The latter may cause a defective expression of HLA class I antigen-tumor antigen derived peptide complexes which mediate the interaction of tumor cells with cognate CTLs. The molecular mechanism(s) underlying the defects in HLA class I antigen expression in ICC tumors are not known and could not be analyzed in the present study because ICC cell lines with abnormalities in HLA class I antigen expression are not available to us. It is likely that defects in the expression and/or function of APM components play a role in the HLA class I antigen down-regulation we have described, since IHC analysis of a limited number of ICC tumors with mAbs detected down-regulation of several APM components in at least 50% of the tumors analyzed (Figure S3).

Defects in HLA class I antigen expression are not the only escape mechanism utilized by ICC cells to avoid destruction by host immune cells. Our study identified at least two additional distinct potential mechanisms which may be utilized by ICC cells. One is represented by PD-L1 expression, which we found to be expressed on ICC cells in about 30% of the tumors analyzed. This frequency is similar to that described in breast
cancer, but lower than that observed in melanoma and ovarian cancer (32-34). By interacting with its receptor, PD-L1 may co-inhibit the activation of CTLs. In addition, reactive nitrogen species (RNS), which are secreted by ICC cells, as shown by the presence of nitrated tyrosines, may inhibit migration of CTLs to the tumor lobules (31). This mechanism could explain the uneven distribution of T cell infiltration in TLs and FS, since we have found an inverse relationship between nitrotyrosine expression and degree of T cell infiltration.

To the best of our knowledge this study is the only one to have analyzed HLA class I antigen expression in ICC tumors, and to have shown that defects in HLA class I antigen expression are present also in this type of tumor. The frequency of HLA class I antigen defects in ICC appears to be similar to that which has been described in breast cancer and prostate cancer, but higher than that described in melanoma and renal cell carcinoma (20). It is of interest that the gene products of the HLA-A locus appear to be less expressed than those of the HLA-B and C loci, provided that this difference does not reflect the different characteristics of the antibodies utilized for staining. On the other hand, HLA class II antigen expression has already been studied by Chou et al., and their results are similar to ours in terms of frequency of HLA class II antigen expression (35). The frequency of HLA class II antigen expression in ICC tumors is similar to that described in adenocarcinoma of the lung and colon cancer, but lower than that observed in renal cell carcinoma (20). The frequency of PD-L1 expression in the ICC tumors we analyzed is significantly lower than that reported by Ye at al. in 31 tumors (100.0%) and by Suleiman et al. in 37 tumors (94.6%) (36, 37). This difference
may reflect the different characteristics of the PD-L1-specific mAbs used in the two published studies and in ours.

As observed in other types of malignancies, HLA class I antigen expression was associated with CD8+ T lymphocyte infiltrate. Whether this association reflects the attraction of cognate CTLs to tumor sites expressing the targeted HLA class I antigen-tumor antigen derived peptide complexes or the induction or up-regulation of HLA class I antigen by IFN-γ secreted by tumor-infiltrating lymphocytes remains to be determined. The latter cytokine is likely to play a role also in the expression of PD-L1 by tumor cells, however IFN-γ does not appear to be the only player in inducing PD-L1 expression since this molecule was not detected on malignant cells in a number of tumors with a high lymphocyte infiltrate.

Neither HLA class I antigens nor PD-L1 or PD-1 alone were associated with the clinical course of the disease. However analysis of HLA class I antigen and PD-L1 expression was found to be statistically correlated with patient outcome. This finding is not unique of ICC, since it has recently been described also in patients with hepatocellular carcinoma (HCC)(38). These results suggest that the failure of patients’ immune system to control tumor growth may reflect not only defects in the effector phase of the immune response, but also loss of susceptibility of targeted tumor cells to immune destruction.

Given the paucity of effective therapies for the treatment of ICC and the recent major successes of immunotherapy with checkpoint molecule-specific mAbs in various types of malignancies, our results deserve some comments given their relevance for the identification of potential prognostic biomarkers and for the optimization of the rational
design of immunotherapeutic strategies in this type of malignancy. First, HLA class I antigen expression in combination with PD-L1 expression by tumor cells may provide useful information about the prognosis in ICC patients, although this possibility has to be substantiated in a prospective study which enrolls a much larger number of patients than that investigated in the present retrospective study. Second, ICC patients may benefit from immunotherapeutic strategies utilizing PD-1- and PD-L1-specific mAbs since these molecules are expressed in ICC lesions. Third, HLA class I antigen expression by tumor cells needs to be taken into account when selecting ICC patients who may be eligible for treatment with checkpoint molecule-specific mAbs; in our study this corresponded to approximately 20% of the patients. Lastly, strategies to increase HLA class I antigen expression by ICC cells may improve the efficacy of checkpoint molecule-specific mAbs-based immunotherapy, since the number of tumor-infiltrating lymphocytes in tumors expressing HLA class I antigens is higher than that in tumors with down-regulated HLA class I antigen expression.

Acknowledgements

The authors would like to acknowledge Ms. Ann S. Adams for her expert editorial assistance.
FIGURE LEGENDS

Figure 1. Representative staining patterns of formalin-fixed, paraffin-embedded primary ICC lesions with CD8- (A, B) and CD4- (C, D) specific mAbs in the FS (A, C) and TLs (B, D) of ICC lesions. E-H. Representative staining patterns of formalin-fixed, paraffin-embedded primary ICC lesions with HLA class I antigen-specific mAbs. Tumor tissue sections were IHC stained with a pool of mouse HLA-A-specific mAb HCA2 and HLA-B/C-specific mAb HC-10 (ratio, 1:1). The staining with HLA class I antigen-specific mAbs was scored as negative (E), heterogeneous (F) and positive (G). Representative staining of FS of ICC lesion with HLA class I antigen-specific mAbs is shown (H). Magnification is indicated.

Figure 2. Correlation between HLA class I antigen expression and number of CD8+ T cells infiltrating the FS (A) and the TLs (B) in ICC lesions. Negative, heterogeneous and positive HLA class I antigen expression is indicated with 0, 1 and 2, respectively. On each box, the central mark is the median, the edges of the box are the 25th and 75th percentiles, the whiskers extend to the most extreme data points not considered outliers, and outliers are plotted individually.

Figure 3. Representative staining patterns of FS (A) and TLs (B, C) of formalin-fixed, paraffin-embedded primary ICC lesions with PD-1-specific mAb. H&E staining of tumor tissue section provides orientation (D). Representative tumor cell staining patterns (E marginal/interface; F and G diffuse; H patchy;) of formalin-fixed, paraffin-embedded primary ICC lesions with PD-L1-specific mAb. Magnification is indicated.
Figure 4. Correlation between HLA class I antigen expression in combination with PD-L1 expression and number of CD8+ T cells infiltrating in ICC lesions. Number of CD8+ T cells infiltrating the FS (A) and the TLs (B) in patients with negative/rare PD-L1 and positive HLA class I antigen expression (indicated with 1) was higher than that in patients with high PD-L1 expression (PD-L1 score ≥ 2), negative/heterogeneous HLA class I antigen expression or a combination of both (indicated with 0). On each box, the central mark is the median, the edges of the box are the 25th and 75th percentiles, the whiskers extend to the most extreme data points not considered outliers, and outliers are plotted individually.

Figure 5. Association of HLA class I antigen and PD-L1 expression in primary ICC lesions with OS in patients with ICC. A. The OS of patients with lesions grouped based on AJCC stage system was compared using the Kaplan-Meier method. Stage group of ICC lesions is indicated. Differences in patients’ survival were analyzed using a log-rank test. B. The OS of patients with lesions stained with a positive HLA class I antigen expression in combination with negative/rare PD-L1 expression and that of lesions with high PD-L1 expression (PD-L1 score ≥ 2), negative/heterogeneous HLA class I antigen expression or a combination of both were compared using the Kaplan-Meier method. Differences in patients’ survival were analyzed using a log-rank test. C. Patients were stratified on HLA class I antigen expression as those with positive or negative/heterogeneous ICC. Then the OS of patients with lesions stained with high PD-L1 expression (PD-L1 score ≥ 2) was compared to that of patients with
negative/rare PD-L1 expression using the Kaplan-Meier method. Differences in patients’ survival were analyzed using a log-rank test.

REFERENCES


Figure 2

A

Number of CD8+ cells in FS

HLA class I antigen expression

B

Number of CD8+ cells in TLs

HLA class I antigen expression
Figure 3

A
Tumor
Normal tissue
200X

B

C

D

Figure 3

E
Tumor
Normal tissue
200x

F

G

H

Downloaded from clincancerres.aacrjournals.org on July 19, 2017. © 2015 American Association for Cancer Research.
Figure 4

A

Number of CD8+ cells in FS

HLA class I antigen/PD-L1 expression

B

Number of CD8+ cells in TLs

HLA class I antigen/PD-L1 expression
Figure A: Kaplan-Meier survival curves for different stages of cancer.

Figure B: Kaplan-Meier survival curves for immune-related markers.

Figure C: Kaplan-Meier survival curves for different HLA class I statuses.
### Table 1 – Patient and tumor characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median age</strong></td>
<td>64.0 years (38-81)</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>14 (51.9%)</td>
</tr>
<tr>
<td>Male</td>
<td>13 (48.1%)</td>
</tr>
<tr>
<td><strong>AJCC stage</strong></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>8 (29.7%)</td>
</tr>
<tr>
<td>II</td>
<td>6 (22.2%)</td>
</tr>
<tr>
<td>III</td>
<td>3 (11.1%)</td>
</tr>
<tr>
<td>IVA</td>
<td>10 (37.0%)</td>
</tr>
<tr>
<td><strong>TNM</strong></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>8 (29.6%)</td>
</tr>
<tr>
<td>T2</td>
<td>8 (29.6%)</td>
</tr>
<tr>
<td>T3</td>
<td>10 (37.0%)</td>
</tr>
<tr>
<td>T4</td>
<td>1 (3.7%)</td>
</tr>
<tr>
<td>N0</td>
<td>18 (66.7%)</td>
</tr>
<tr>
<td>N1</td>
<td>9 (33.3%)</td>
</tr>
<tr>
<td>M1</td>
<td>0 (0%)</td>
</tr>
<tr>
<td><strong>Grade of differentiation</strong></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>19 (70.4%)</td>
</tr>
<tr>
<td>Poor</td>
<td>8 (29.6%)</td>
</tr>
<tr>
<td><strong>Single lesion</strong></td>
<td>18 (66.7%)</td>
</tr>
<tr>
<td><strong>Multiple lesions</strong></td>
<td>9 (33.3%)</td>
</tr>
<tr>
<td><strong>No vascular invasion</strong></td>
<td>16 (59.3%)</td>
</tr>
<tr>
<td><strong>Vascular invasion</strong></td>
<td>11 (40.7%)</td>
</tr>
<tr>
<td><strong>Margin of resection</strong></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>24 (88.9%)</td>
</tr>
<tr>
<td>Positive</td>
<td>3 (11.1%)</td>
</tr>
<tr>
<td><strong>Median follow up</strong></td>
<td>29.1 months (3.8-105.8)</td>
</tr>
<tr>
<td><strong>Median OS</strong></td>
<td>44.6 months (14.9-105.8)</td>
</tr>
</tbody>
</table>
Clinical Cancer Research

PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma

Francesco Sabbatino, Vincenzo Villani, Jennifer H Yearley, et al.

Clin Cancer Res Published OnlineFirst September 15, 2015.

Updated version
Access the most recent version of this article at:

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2015/09/15/1078-0432.CCR-15-0715.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.